HomeInfo CentreNewsDZ13 skin cancer drug trials suspended

DZ13 skin cancer drug trials suspended

  • August 15, 2013
  • Posted by: Spotscreen
  • Category: News
No Comments

There has been serious speculation surrounding the accuracy of scientific research data on skin cancer drug DZ13 conducted at the University of NSW.

This has caused the University to suspend patient trials of the drug which was anticipated to be a significant step forward in skin cancer treatment.

The call was made to stop the skin cancer trials after Professor David Vaux, an internationally acclaimed cell scientist,  raised the alarm.

Professor Vaux became concerned about the accuracy of the data after seeing duplicate images in medical research journals.

Read More Here

 

______________

Spotscreen are Australia’s onsite skin cancer screening specialists, visiting workplaces in both metro and regional areas of Australia.

For information on how Spotscreen can help with your next onsite skin cancer screening program, please contact (08) 9467 0914.

 



Author: Spotscreen
Spotscreen is Australia’s leading onsite skin cancer screening and corporate health provider, focussing on providing the highest quality of specialised onsite health programs for your workplace and local community.